Prelude Therapeutics Inc (PRLD)

$1.29 +0.07 (5.33%)
Market Cap 71.88M
Revenue (ttm) 7.00M
Net Income (ttm) -127.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,816.71%
Debt to Equity Ratio 0.00
Volume 344,227
Avg Vol 181,340
Day's Range N/A - N/A
Shares Out 56.60M
Stochastic %K 83%
Beta 1.22
Analysts Sell
Price Target $3.50

Company Profile

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 467 1280
Address:
175 Innovation Boulevard, Wilmington, United States
StockScanners
StockScanners Aug. 23 at 6:44 PM
$PRLD reached 1.29, nice continuation we got, lets go team
0 · Reply
StockScanners
StockScanners Aug. 23 at 6:43 PM
$PRLD we catch any idea, slow and low volume, we still spot opportunity, reached 1.32
0 · Reply
StockScanners
StockScanners Aug. 23 at 5:57 PM
$PRLD keep watch if this holds above 1.20
0 · Reply
BobBijawklah
BobBijawklah Aug. 23 at 3:55 PM
$PRLD there are more chemical formulations on the patent page than just these check them out all way at bottom of page.does t specifically reference which drug patent is for https://patents.justia.com/patent/12129262. https://patents.justia.com/patent/11939340 https://patents.justia.com/patent/11939340 https://patents.justia.com/patent/11939340
1 · Reply
LabPsycho
LabPsycho Aug. 22 at 1:10 PM
$PRLD @BobBijawklah Thanks for your efforts. I have seen that image and it's a concern for me they basically just drew two random shapes where they think it fits in the protein complex. Well it's possible they do not have a protein structure complex of their molecule I cannot find the chemical structure of any of their compounds. This is at least a yellow flag for me if not a red flag. I've not done a thorough search but even patent literature not showing anything. At least with cccc I was able to find a close approximation to one of the structures of their drug from the patent literature and from that able to do a reasonable molecular simulation.
2 · Reply
StockScanners
StockScanners Aug. 22 at 5:54 AM
$PRLD reached 1.21
0 · Reply
BobBijawklah
BobBijawklah Aug. 21 at 9:16 PM
$PRLD prt2527 look at the group of people that were granted preclinical data and trial deatials back in nov 2024 . Astra zenaca , Merck , Celegene, J&J , Abbvie , ect ect
2 · Reply
BobBijawklah
BobBijawklah Aug. 21 at 9:02 PM
$PRLD Lab Psycho here is the best i could get you on the pharmacological makeup of prt7732. now interesting point that the oral degrader has a 3000 fold sensitivity to SMARCA2/4. So oral is a much easier addon and i tend to believe they know that this is the lead compound that they are going to take to market in future. https://investors.preludetx.com/static-files/98d7ba33-ac65-48dc-a50e-a087a0e1ff03#:~:text=PRT7732/CRBN%2DDDB1%20E3%20Ligase,%3E3000%20fold
1 · Reply
LabPsycho
LabPsycho Aug. 21 at 5:33 PM
$PRLD Sucker rally this a.m. or harbinger of a 40% short term gain potential? See below...not staying at 85 cents...the signal was there a month ago for me. Good luck
0 · Reply
Dizzier47
Dizzier47 Aug. 21 at 10:49 AM
$PRLD maybe maybe not
0 · Reply
Latest News on PRLD
Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 7:00 AM EDT - 13 days ago

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Jun 2, 2025, 7:30 AM EDT - 3 months ago

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025, 4:05 PM EDT - 4 months ago

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

May 1, 2025, 7:30 AM EDT - 4 months ago

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

Prelude Announces Presentations at 2025 AACR Annual Meeting

Apr 25, 2025, 4:05 PM EDT - 4 months ago

Prelude Announces Presentations at 2025 AACR Annual Meeting

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Mar 10, 2025, 7:30 AM EDT - 6 months ago

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

Mar 5, 2025, 7:30 AM EST - 6 months ago

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Dec 11, 2024, 7:30 AM EST - 9 months ago

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

Nov 27, 2024, 7:30 AM EST - 9 months ago

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

Oct 24, 2024, 7:30 AM EDT - 10 months ago

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

Oct 9, 2024, 7:30 AM EDT - 11 months ago

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Sep 13, 2024, 10:00 AM EDT - 1 year ago

Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 7:01 AM EDT - 1 year ago

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

Jul 9, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

May 9, 2024, 7:01 AM EDT - 1 year ago

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 7:01 AM EDT - 1 year ago

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Apr 9, 2024, 4:35 PM EDT - 1 year ago

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

Mar 5, 2024, 4:45 PM EST - 1 year ago

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

Feb 29, 2024, 4:05 PM EST - 1 year ago

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

Feb 15, 2024, 4:05 PM EST - 1 year ago

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

Prelude Therapeutics Announces $25 Million Private Placement

Dec 11, 2023, 9:34 AM EST - 1 year ago

Prelude Therapeutics Announces $25 Million Private Placement

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

Nov 1, 2023, 4:10 PM EDT - 1 year ago

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

Oct 14, 2023, 12:30 PM EDT - 2 years ago

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

Aug 29, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

May 31, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

Prelude Therapeutics Announces Launch of Proposed Public Offering

May 17, 2023, 4:08 PM EDT - 2 years ago

Prelude Therapeutics Announces Launch of Proposed Public Offering

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

May 8, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

Apr 27, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

Apr 11, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 15, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

Mar 15, 2023, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

Feb 9, 2023, 9:05 AM EST - 2 years ago

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

Nov 14, 2022, 8:00 AM EST - 3 years ago

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

Aug 9, 2022, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

May 10, 2022, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

Prelude Therapeutics Reports Full Year 2021 Financial Results

Mar 16, 2022, 7:30 AM EDT - 3 years ago

Prelude Therapeutics Reports Full Year 2021 Financial Results

Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference

Mar 11, 2022, 8:00 AM EST - 3 years ago

Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference

Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting

Mar 9, 2022, 8:05 AM EST - 3 years ago

Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting

Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Feb 11, 2022, 7:00 AM EST - 3 years ago

Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

Jan 4, 2022, 7:00 AM EST - 3 years ago

Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx Conference

Nov 23, 2021, 7:00 AM EST - 4 years ago

Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx Conference

Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update

Nov 12, 2021, 8:00 AM EST - 4 years ago

Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update

Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 Inhibitor

Nov 8, 2021, 9:00 AM EST - 4 years ago

Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 Inhibitor

Why Did Prelude Therapeutics Stock Tumble To 52-Week Low Today?

Oct 7, 2021, 12:55 PM EDT - 4 years ago

Why Did Prelude Therapeutics Stock Tumble To 52-Week Low Today?

Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Oct 7, 2021, 9:00 AM EDT - 4 years ago

Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update

Aug 12, 2021, 7:30 AM EDT - 4 years ago

Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update

Why BofA Is Turning Bullish On Prelude Therapeutics

Jul 27, 2021, 12:32 PM EDT - 4 years ago

Why BofA Is Turning Bullish On Prelude Therapeutics

Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update

May 11, 2021, 7:30 AM EDT - 4 years ago

Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update

StockScanners
StockScanners Aug. 23 at 6:44 PM
$PRLD reached 1.29, nice continuation we got, lets go team
0 · Reply
StockScanners
StockScanners Aug. 23 at 6:43 PM
$PRLD we catch any idea, slow and low volume, we still spot opportunity, reached 1.32
0 · Reply
StockScanners
StockScanners Aug. 23 at 5:57 PM
$PRLD keep watch if this holds above 1.20
0 · Reply
BobBijawklah
BobBijawklah Aug. 23 at 3:55 PM
$PRLD there are more chemical formulations on the patent page than just these check them out all way at bottom of page.does t specifically reference which drug patent is for https://patents.justia.com/patent/12129262. https://patents.justia.com/patent/11939340 https://patents.justia.com/patent/11939340 https://patents.justia.com/patent/11939340
1 · Reply
LabPsycho
LabPsycho Aug. 22 at 1:10 PM
$PRLD @BobBijawklah Thanks for your efforts. I have seen that image and it's a concern for me they basically just drew two random shapes where they think it fits in the protein complex. Well it's possible they do not have a protein structure complex of their molecule I cannot find the chemical structure of any of their compounds. This is at least a yellow flag for me if not a red flag. I've not done a thorough search but even patent literature not showing anything. At least with cccc I was able to find a close approximation to one of the structures of their drug from the patent literature and from that able to do a reasonable molecular simulation.
2 · Reply
StockScanners
StockScanners Aug. 22 at 5:54 AM
$PRLD reached 1.21
0 · Reply
BobBijawklah
BobBijawklah Aug. 21 at 9:16 PM
$PRLD prt2527 look at the group of people that were granted preclinical data and trial deatials back in nov 2024 . Astra zenaca , Merck , Celegene, J&J , Abbvie , ect ect
2 · Reply
BobBijawklah
BobBijawklah Aug. 21 at 9:02 PM
$PRLD Lab Psycho here is the best i could get you on the pharmacological makeup of prt7732. now interesting point that the oral degrader has a 3000 fold sensitivity to SMARCA2/4. So oral is a much easier addon and i tend to believe they know that this is the lead compound that they are going to take to market in future. https://investors.preludetx.com/static-files/98d7ba33-ac65-48dc-a50e-a087a0e1ff03#:~:text=PRT7732/CRBN%2DDDB1%20E3%20Ligase,%3E3000%20fold
1 · Reply
LabPsycho
LabPsycho Aug. 21 at 5:33 PM
$PRLD Sucker rally this a.m. or harbinger of a 40% short term gain potential? See below...not staying at 85 cents...the signal was there a month ago for me. Good luck
0 · Reply
Dizzier47
Dizzier47 Aug. 21 at 10:49 AM
$PRLD maybe maybe not
0 · Reply
Jaybird827
Jaybird827 Aug. 21 at 1:03 AM
$PRLD is this gonna do this for ten days so it doesn’t get delisted?
0 · Reply
StockScanners
StockScanners Aug. 21 at 12:34 AM
$PRLD keep watch if this holds above .98
0 · Reply
Zahid1975
Zahid1975 Aug. 20 at 10:20 PM
$PRLD tomorrow maybe good day for
0 · Reply
Nakuneballe
Nakuneballe Aug. 20 at 4:26 PM
$PRLD
0 · Reply
Drugtrade
Drugtrade Aug. 20 at 4:23 PM
$PRLD insiders really loaded around .70 earlier this year thats direct share purchase could be big
0 · Reply
Dizzier47
Dizzier47 Aug. 20 at 4:19 PM
$PRLD above 1 lesgo
0 · Reply
BobBijawklah
BobBijawklah Aug. 19 at 1:05 PM
$PRLD PRT2527 combo saw a very robust complete and partial response rate in extremely hard to treat lymphatic cancers. Average prior lines of therapy prior to treatment was 3 )range was 1-7. So that is very encouraging preclinical data And PRT7732 from the tone of the update on the 10q is robust and safety should be stellar. I am drawing the conclusion that once PRT7732 data becomes available the stock will double overnight . Then they will likely strike a stock offering. The oral smarc2/4 degrader can most certainly be a major target for acquisition or partnership if the data is as good as i am believing it is. PT 2.00 in next 6 months.
1 · Reply
anachartanalyst
anachartanalyst Aug. 18 at 3:02 PM
$PRLD https://anachart.com/wp-content/uploads/ana_temp/1755529310_soc-img.jpg
0 · Reply
DARKP00L
DARKP00L Aug. 18 at 2:46 PM
$PRLD 10:37 on Aug. 18 2025 JMP Securities Maintains Market Outperform on Prelude Therapeutics, Lowers Price Target to $3 #tradeideas$FUBO 10:42 on Aug. 18 2025 FuboTV Strengthens Premium Sports Lineup With NFL, UEFA, And Ligue 1 In Key Global Markets #tradeideas
0 · Reply
Drugtrade
Drugtrade Aug. 15 at 3:18 PM
$PRLD should have sold over $1 and bought a few here with house $$
0 · Reply
theBigDollarski
theBigDollarski Aug. 14 at 4:04 PM
$PRLD sell now before they burn the rest of their money with nothing to show.....this company is a nothingburger.
0 · Reply
theBigDollarski
theBigDollarski Aug. 14 at 3:59 PM
$PRLD
0 · Reply